BergenBio Fundamentale Forhold (BGBIO)

TekBot · oktober 14, 2020, 5:01am

BERGENBIO PRESENTS DATA ON ANTI-AXL ANTIBODY TILVESTAMAB AT 32[nd] ENA SYMPOSIUM

Bergen, Norway, 14 October 2020 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, announces that pre-clinical data on tilvestamab, the
…

Vis børsmeldingen

Company’s novel function blocking, humanized anti-AXL antibody, will be
presented at an ePoster presentation at the virtual 32[nd] EORTC NCI AACR (ENA)
Symposium.

The data presented shows that tilvestamab prevents AXL mediated cell signaling
in cancer cell lines, reduces cell migration and invasion and shows anti-tumor
efficacy in a panel of mouse xenograft models. Further it is shown that in a non
-human primate dose-ranging toxicokinetic study, tilvestamab was well tolerated
during dosing phase up to the highest studied dose of 25mg/kg. Tilvestamab is
currently being evaluated in a Phase I clinical study (BGB149-101; NCT03795142)
in healthy volunteers to evaluate safety, tolerability and pharmacokinetics.

The meeting will run from October 24-25 2020 and will be fully virtual, with
further information available on the ENA
website (https://event.eortc.org/ena2020/). Full details of the abstract are as
follows:

Title: Tilvestamab, a novel clinical stage humanized anti-AXL function blocking
antibody

Date: Saturday, October 24th 2020
Link to
Abstract (https://cm.eortc.org/cmPortal/Searchable/ENA2020/config/normal#!abstrac
tdetails/0000897260)

END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying many life-threatening diseases. In cancer, AXL
suppresses the body’s immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Robnie · oktober 14, 2020, 6:48am

Det må være gode nyheter

Smania · oktober 14, 2020, 4:51pm

busk1:

AXL Promotes SARS-CoV-2 Infection of Pulmonary and Bronchial Epithelial Cells

De konkluderer med

Taken together, our findings suggest AXL may play an important role in promoting SARS-CoV-2 infection of the human respiratory system and is a potential target in future clinical intervention strategies.

Vel og bra, men så sier de dette i diskusjonsdelen:

As AXL is overexpressed in numerous cancer types, it has already been pursued as a drug target. However, we note that most reported AXL inhibitors target its kinase domain and would thus not have efficacy against SARS-CoV-2 infection because the virus interacts with the extracellular Ig-like domains of AXL ( Figs. 4 g-i ). Alternative approaches include targeting the AXL extracellular Ig-like domains and the region of the SARS-CoV-2 S protein that interacts with AXL. Clinical grade human recombinant soluble AXL may be used to block viral infection ( Figs. 6 c-g ).

Er Bemcentinib av den typen de er skeptiske til (targets the kinase domain)? Noen som kan dette godt nok til å svare?

Svaret her er at ja, bemcentinib er av typen de er skeptiske til. Bemcentinib binder seg til intracellulære kinase-del av AXL, mens covid-19 viruset binder seg en annen plass, utenfor cellen, til Ig-delen av AXL-reseptoren. Imidlertid mener jeg slutningen til kineserne er totalt feil, når de sier at AXL-hemmer som blokkerer kinase-del ikke vil kunne ha effekt mot Covid-19, av den grunn. Forklaringen er at viruset bruker AXL-reseptor til å komme inn i cellen ved hjelp av “apoptotic mimecry”. Den “utgir” seg for å være en død celle, og blir så aktivt tatt opp av cellen den binder seg til, vha AXL. For å aktivere denne prosessen må reseptoren aktiveres, og denne aktiveringen fungerer ikke når kinase-delen er inaktivert. Det nytter ikke for viruset å “henge på” målcellen vha AXL-reseptoren, når bemcentinib hindrer AXL fra å fungere, slik at viruset ikke blir tatt inn i cellen. Bildet under hentet fra BergenBio sin webcast 29.april

Londonmannen · oktober 14, 2020, 5:26pm

Se det! Interessant. Og det bidrar ikke akkurat til å redusere mine forventninger til hvilket utkomme vi vil få mhp Bemcentinib sin effekt mot Covid-19. Og den dagen vi eventuelt får en bekreftelse på at Bemcentinib har positiv effekt, da blir det moro å være BgBio aksjonær! Særdeles moro!

TekBot · oktober 15, 2020, 5:01am

BERGENBIO TO PRESENT CLINICAL TRANSLATIONAL DATA FROM THE ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN NSCLC AT ANNUAL SITC MEETING

Bergen, Norway, 15 October 2020 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, is pleased to announce that it has been selected for
…

Vis børsmeldingen

an oral presentation at the Society for Immunotherapy of Cancer (SITC) 35[th]
Annual Meeting, taking place online from 9-14 November 2020.

Abstract titles have been announced online
here (https://sitc.sitcancer.org/2020/abstracts/titles/index.php?filter=bemcentin
ib). BerGenBio will present clinical translational research updates from its
Phase II bemcentinib and pembrolizumab combination study (BGBC008) in advanced
non-small cell lung cancer (NSCLC), as part of the Combinatorial Therapies
session on 11[ ]November. Full details of the presentation are below.

Title: A PhII study of bemcentinib, a first-in-class selective AXL kinase
inhibitor, in combination with pembrolizumab in pts with previously-treated
advanced NSCLC: Updated clinical & translational analysis

Author: Professor James Spicer, Professor of Experimental Cancer Medicine at
King’s College London

Session/Abstract ID: Combinatorial Therapies, 362

Date/Time: 11 November 2020, 11.40am EST

The presentation will be made available on BerGenBio’s website, under
‘Presentations (https://www.bergenbio.com/investors/presentations/)’.

END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases. In cancer, AXL
suppresses the body’s immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

larosaleda · oktober 19, 2020, 8:37am

2 abstrakter fra databasen til WHO som jeg finner interessante. Er noe uklart når de blev lagt til men jeg finner de ikke i tråden og det er ikke mindre aktuellt nå som “solidarity” vurderer nye kandidater. Bemcentinib er nevnt i begge:

TekBot · oktober 21, 2020, 9:37am

BERGENBIO CONFIRMS FIRST PATIENT ENROLLED IN PHASE II TRIAL ASSESSING BEMCENTINIB AS A POTENTIAL TREATMENT FOR COVID-19 PATIENTS IN SOUTH AFRICA

Bergen, Norway - 21 October 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today announces that the first patient has
…

Vis børsmeldingen

been enrolled in the company sponsored Phase II clinical trial (BGBC020),
assessing the efficacy and safety of bemcentinib for the treatment of
hospitalised COVID-19 patients in South Africa and India.

The Phase II study will recruit 120 hospitalised COVID-19 patients across five
sites in South Africa and seven sites in India. 60 patients will receive
bemcentinib (as monotherapy or in combination with standard of care medication)
and 60 patients in a control group (receiving standard of care treatment only).

The primary endpoint of the trial will be time to clinical improvement of at
least two points (from randomisation) on a nine-point ordinal scale, or live
discharge from the hospital, whichever comes first. The trial protocol will
permit co-administration with other medicines recommended for treatment of COVID
-19, including remdesivir and dexamethasone. A Data Monitoring Committee (DMC)
formed of a group of independent experts external to the study has been
established. The DMC will assess the progress, safety data and, critical
efficacy endpoints of the trial as it proceeds.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We
are excited to continue exploring the profile of bemcentinib as a potential
treatment for hospitalised COVID-19 patients and are delighted to announce
that the study has commenced in South Africa. The region remains a geographical
location of high incidence and we look forward to
accelerating recruitment in South Africa and India, and providing further
updates on our progress in due course.”

END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying many life-threatening diseases. In cancer, AXL
suppresses the body’s immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung
cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In parallel,
BerGenBio is developing companion diagnostic tests to identify patient
populations most likely to benefit from bemcentinib: this is expected to
facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · oktober 23, 2020, 5:02am

BERGENBIO VIRTUAL R&D DAY - 06 NOVEMBER 2020

Bergen, Norway, 23[rd] October 2020 - BerGenBio ASA (OSE:BGBIO), a clinical
-stage biopharmaceutical company developing novel, selective AXL kinase
inhibitors for severe unmet medical need, is pleased to announce that it will
…
Vis børsmeldingen

host a virtual R&D Day on 06 November 2020 from 13.00 CET.

The event will feature independent experts highlighting the role of AXL kinase
as an essential mediator of the biological mechanisms underlying life
-threatening diseases. The presentations will focus on the role of AXL in
specific disease areas including oncology, fibrosis and infectious disease such
as COVID-19. Each presentation will be followed by a Q&A session.

A preliminary program for the event is outlined below. To register, please click
here (bergenbio@consilium
-comms.com?subject=I%20would%20like%20to%20attend%20the%20BerGenBio%20Virtual%20E
vent).
              Preliminary Agenda
                (times in CET)
13:00 Introduction - Richard
Godfrey, Chief Executive
Officer, BerGenBio

13:10 AXL in AML/MDS
- Professor Sonja
Loges, Director,
Department
of Personalised Oncology,
University Hospital
Mannheim and Division
of Personalised Medical
Oncology, German Research
Center - DKFZ
(Heidelberg, Germany)
13:40 AXL in lung cancer - Dr
Matthew Krebs, Clinical
Senior Lecturer in
Experimental Cancer
Medicine and Honorary
Consultant in Medical
Oncology, The Christie
NHS Foundation Trust
(Manchester, UK)
14:10 AXL and viruses/COVID-19
- Professor Wendy Maury,
Professor of Microbiology
and Immunology,
University of Iowa (Iowa
City, USA)
14:40 AXL in fibrosis/IPF -
Professor Cory Hogaboam,
Professor of Medicine,
Cedars-Sinai Medical
Center (Los Angeles, USA)
15:10 Bemcentinib clinical
development plan - Hani
Gabra, Chief Medical
Officer, BerGenBio
15:25 Concluding remarks -
Richard Godfrey, Chief
Executive Officer,
BerGenBio
For further information, please contact Consilium
Strategic Communications at bergenbio@consilium
-comms.com or
i (ir@bergenbio.com)r@bergenbio.co (ir@bergenbio.com)m

END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases. In cancer, AXL
suppresses the body’s immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing a companion diagnostic test to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Fornybar · oktober 23, 2020, 5:21am

Resten av året begynner å virke spennende for BergenBio.

R&D Day 06 November
SITC Lungekreft 10-15 November
Q3 med Covid-oppdatering 17 November
ASH 5-8 Desember

MY GUESS IS at den nye strategien for å nå førstelinje i lungekreft blir lansert på R&D-dagen. Dette ble nevnt av Godfrey som noe de ville kommunisere i år, og jeg greier ikke se et bedre tidspunkt. Vi vet fra Vaccibodyanalysen at førstelinje i lungekreft er noe som er EKSTREMT verdifullt når man regner på det, så her burde kursmålene løpe løpsk hvis man må regne inn en registreringsstudie her.

eiken · oktober 23, 2020, 5:47am

Må ikke glemme morgendagen.

Fornybar · oktober 23, 2020, 5:49am

Hva skjer i morgen?

tekdude · oktober 23, 2020, 5:50am

alfred_e_neuman · oktober 24, 2020, 3:13pm

AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer

https://www.cell.com/iscience/fulltext/S2589-0042(20)30841-5 (DOI)

Published: October 07, 2020

We hypothesized that AXL is a driver of stemness traits in cancer by co-option of a regulatory function normally reserved for stem cells. AXL-expressing cells in human mammary epithelial ducts co-expressed markers associated with multipotency, and AXL inhibition abolished colony formation and self-maintenance activities while promoting terminal differentiation in vitro .

Secondary mammosphere formation was not affected by treatment with imatinib, but was reduced more than 4-fold by treatment with the AXL-inhibitor bemcentinib. Formation of multi-lineage acini in 3D laminin-rich ECM (lrECM) was also significantly inhibited by treatment with bemcentinib, and only a few single K19-staining cells were observed in culture post-treatment.

AXL knockdown significantly decreased tumor incidence independent of SNAI2/Slug overexpression in this model. […] Tumorsphere formation with 4T1 cells was nearly abolished by treatment with warfarin (3uM) or with bemcentinib (900 nM). Pretreatment of 4TL with paclitaxel (3 nM) reduced tumor incidence following implantation, and pretreatment with paclitaxel and bemcentinib (600 nM) completely prevented tumor formation. Furthermore, bemcentinib administered in vivo (both 50 and 100 mg/kg) decreased 4T1 tumor growth in syngeneic host mice. These results support the notion that AXL is required to sustain epithelial plasticity traits that facilitate tumor formation in mammary glands.

(Bemcentinib, also known as BGB324 or R428)

TekBot · oktober 28, 2020, 3:41pm

BerGenBio ASA: Primary Insider notification

Investor6 · oktober 28, 2020, 4:08pm

Bra at Trond støttekjøper nå!

TekBot · oktober 30, 2020, 3:40pm

BerGenBio ASA: Primary Insider notification

prump · oktober 30, 2020, 3:45pm

Legend!

Investor6 · oktober 30, 2020, 4:39pm

Trond trår til igjen!
Ser ut til å kunne bli en kamp mellom Trond og gutta i kortbukser dette !

Dreamliner · oktober 30, 2020, 5:06pm

Det er ikke umulig at Bemcentinib blir den beste løsningen på denne pandemien. I hvert fall hindre en masse dødsfall. Har veldig liten tro på at vaksinene vil gi særlig lang immunitet når ikke sykdommen selv gjør det.
Skulle tro at man får nok av pasienter til å være med på Accord testene i UK. De neste to månedene blir veldig spennende.

Hayen · oktober 30, 2020, 5:14pm

Innleggelser i UK forsetter akselerasjonen.

Sist kjente døgn (26 oktober) ble det lagt inn 1489.
Det er ca 15x mer enn for to mnd siden.

Myndighetene i UK skal ha kred for at de var raskt med å få igang Accord da de så hva som var i ferd med å skje.